Cholinergic receptors as target for cancer therapy in a systems medicine perspective

Current Molecular Medicine

Volumn 14, Issue 9, 2014, Pages 1126-1138

  Russo, P ^a   Del Bufalo, A ^a   Milic, M ^a,b   Salinaro, G ^a   Fini, M ^a   Cesario, A ^a  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

^b INSTITUTE FOR MEDICAL RESEARCH AND OCCUPATIONAL HEALTH   (Croatia)

Author keywords

ACh; Complex disease; Drug discovery and development; mAChR; nAChR; Systems biology; Systems medicine; Therapy

Indexed keywords

BETA ARRESTIN; BETA CATENIN; BUNGAROTOXIN RECEPTOR; CALPAIN 1; CHOLINERGIC RECEPTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERSTITIAL COLLAGENASE; JANUS KINASE; MATRILYSIN; MITOGEN ACTIVATED PROTEIN KINASE; MUSCARINIC RECEPTOR; NICOTINIC RECEPTOR; PROSTAGLANDIN E2; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; STAT PROTEIN; STROMELYSIN 2; SURVIVIN; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR ZEB1; UVOMORULIN; X LINKED INHIBITOR OF APOPTOSIS; ANTINEOPLASTIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT;

APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER THERAPY; CELL PROLIFERATION; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENETIC ASSOCIATION; HUMAN; INTRACELLULAR SIGNALING; METASTASIS; NEOPLASM; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR AFFINITY; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; UPREGULATION; ANIMAL; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; CHOLINERGIC ANTAGONISTS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, CHOLINERGIC; SIGNAL TRANSDUCTION;

EID: 84926317306     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/1566524014666141015152601     Document Type: Article

References (113)

1. Wessler I, Kilbinger H, Bittinger F, Kirkpatric CJ. The biological role of non-neuronal acetylcholine in plants and humans. Jpn J Pharmacol 2001; 85: 2-10.
2. Russo P, Cardinale A, Schuller H. A new “era” for the α7-nAChR. Curr Drug Targets 2012, 13: 721-725.
3. Amenta F, Tayebati SK. Pathways of acetylcholine synthesis, transport and release as targets for treatment of adult-onset cognitive dysfunction. Curr Med Chem 2008; 15: 488-498.
4. Paleari L, Grozio A, Cesario A, Russo P. The cholinergic system and cancer. Semin Cancer Biol 2008; 18: 211-217.
5. Darvesh S, Hopkins DA, Geulam C. Neurobiology of butyrylcholinesterase. Nat Rev Neurosci 2003; 4: 131-138.
6. Gahring LC, Vasquez-Opazo GA, Rogers SW. Choline promotes nicotinic receptor alpha4 + beta2 up-regulation. J Biol Chem 2010; 285: 19793-19801.
7. Taly A, Corringer PJ, Guedin D, Lestage P, Changeux JP. Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system. Nat Rev Drug Discov 2009; 8: 733-750.
8. Russo P, Taly A. α7-Nicotinic acetylcholine receptors: an old actor for new different roles. Curr Drug Targets 2012; 13: 574-578.
9. Le Novere N, Corringer PJ, Changeux JP. The diversity of subunit composition in nAChRs: evolutionary origins, physiologic and pharmacologic consequences. J Neurobiol 2002; 53: 447-456.
10. Caulfield MP, Birdsall NJ. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev 1998; 50: 279-290.
11. Hassall CJ, Stanford SC, Burnstock G, Buckley NJ. Coexpression of four muscarinic receptor genes by the intrinsic neurons of the rat and guinea pig heart. Neuroscience 1993; 56: 1041-1048.
12. Katz A, Wu D, Simon MI. Subunits is βγof heterotrimeric G protein activate b2 isoform of phospholipase C. Nature 1992; 360: 686-689.
13. Kruse AC, Hu J, Pan AC, et al. Structure and dynamics of the M3 muscarinic acetylcholine receptor. Nature 2012; 482: 552-556.
14. Nemec J, Wickman K, Clapham DE. Gbetagamma binding increases the open time of IKACh: Kinetic evidence for multiple Gbetagamma binding sites. Biophys J 1999; 76: 246-252.
15. Nathanson NM. A multiplicity of muscarinic mechanisms: Enough signaling pathways to take your breath away. Proc Natl Acad Sci USA 2000; 97: 6245-6247.
16. Marinissen MJ, Gutkind JS. G-protein-coupled receptors and signaling networks: emerging paradigms. Trends Pharmacol Sci 2001; 22: 368-376.
17. Wessler I, Kirkpatrick CJ. Acetylcholine beyond neurons: the non-neuronal cholinergic system in humans. Br J Pharmacol 2008; 154: 1558-1571.
18. Kawashima K, Fujii T. Basic and clinical aspects of nonneuronal acetylcholine: overview of non-neuronal cholinergic systems and their biological significance. J Pharmacol Sci 2008; 106: 167-173.
19. Paleari L, Cesario A, Fini M, Russo P. alpha7-Nicotinic receptor antagonists at the beginning of a clinical era for NSCLC and Mesothelioma? Drug Discov Today 2009; 14: 822-836.
20. Wessler IK, Kirkpatrick CJ. Activation of muscarinic receptors by non-neuronal acetylcholine. Handb Exp Pharmacol 2012; 208: 469-491.
21. Cardinale A, Nastrucci C, Cesario A, Russo P. Nicotine: specific role in angiogenesis, proliferation and apoptosis. Crit Rev Toxicol 2012; 42: 68-89.
22. Nastrucci C, Russ, P. α7 nAChR in airway respiratory epithelial cells. Curr Drug Targets 2012; 13: 666-670.
23. Grando SA, Pittelkow MR, Schallreuter KU. Adrenergic and cholinergic control in the biology of epidermis: physiological and clinical significance. J Invest Dermatol 2006; 126: 1948-1965.
24. Fu XW, Rekow SS, Spindel ER. The ly-6 protein, lynx1 is an endogenous inhibitor of nicotinic signaling in airway epithelium. Am J Physiol Lung Cell Mol Physiol 2012; 303: L661-8.
25. Russo P, Nastrucci C, Alzetta G, Szalai C. Tobacco habit: historical, cultural, neurobiological, and genetic features of people's relationship with an addictive drug. Perspect Biol Med 2011; 54: 557-577.
26. Barik J, Wonnacott S. Molecular and cellular mechanisms of action of nicotine in the CNS. Handb Exp Pharmacol 2009; 192: 173-207.
27. Pillai S, Chellappan S. α7 nicotinic acetylcholine receptor subunit in angiogenesis and epithelial to mesenchymal transition. Curr Drug Targets 2012; 13: 671-679.
28. Govind AP, Vezina P, Green WN. Nicotine-induced upregulation of nicotinic receptors: underlying mechanisms and relevance to nicotine addiction. Biochem Pharmacol 2009; 78: 756-765.
29. Schuller HM. Regulatory role of the α7nAChR in cancer. Curr Drug Targets 2012; 13: 680-687.
30. Schuller HM, Orloff M. Tobacco-specific carcinogenic nitrosamines. Ligands for nicotinic acetylcholine receptors in human lung cancer cells. Biochem Pharmacol 1998; 55: 1377-1384.
31. Schuller HM. Is cancer triggered by altered signalling of nicotinic acetylcholine receptors? Nat Rev Cancer 2009; 9: 195-205.
32. Egleton RD, Brown KC, Dasgupta P. Nicotinic acetylcholine receptors in cancer: multiple roles in proliferation and inhibition of apoptosis. Trends Pharmacol Sci 2008; 29: 151-158.
33. Song P; Spindel ER. Basic and clinical aspects of nonneuronal acetylcholine: expression of non-neuronal acetylcholine in lung cancer provides a new target for cancer therapy. J Pharmacol Sci 2008; 106: 180-185.
34. Russo P, Cardinale A, Margaritora S, Cesario A. Nicotinic receptor and tobacco-related cancer. Life Sci 2012; 91: 1087-1092.
35. Chernyavsky AI, Arredondo J, Galitovskiy V, Qian J, Grando SA. Upregulation of nuclear factor-kappaB expression by SLURP-1 is mediated by alpha7-nicotinic acetylcholine receptor and involves both ionic events and activation of protein kinases. Am J Physiol Cell Physiol 2010; 299: C903-911.
36. Pettersson A, Nylund G, Khorram-Manesh A, Nordgren S, Delbro DS. Nicotine induced modulation of SLURP-1 expression in human colon cancer cells. Auton Neurosci 2009; 148: 97-100.
37. Elgoyhen AB, Johnson DS, Boulter J, Vetter DE, Heinemann S. Alpha 9: an acetylcholine receptor with novel pharmacological properties expressed in rat cochlear hair cells. Cell 1994; 79: 705-715.
38. Guth PS, Norris CH. The hair cell acetylcholine receptors: a synthesis. Hear Res 1996; 98: 1-8.
39. Katz E, Verbitsky M, Rothlin CV, et al. High calcium permeability and calcium block of the alpha9 nicotinic acetylcholine receptor. Hear Res 2000; 141: 117-128.
40. Sgard F, Charpantier E, Bertrand S, et al. A novel human nicotinic receptor subunit, alpha10, that confers functionality to the alpha9-subunit. Mol Pharmacol 2002; 61: 150-159.
41. Lee CH, Huang CS, Chen CS, et al. Overexpression and activation of the alpha9-nicotinic receptor during tumorigenesis in human breast epithelial cells. J Natl Cancer Inst 2010; 102: 1322-1335.
42. Shah N, Khurana S, Cheng K, Raufman JP. Muscarinic receptors and ligands in cancer. Am J Physiol Cell Physiol 2009; 296: C221-232.
43. Spindel ER. Muscarinic receptor agonists and antagonists: effects on cancer. Handb Exp Pharmacol 2012; 208: 451-468.
44. Haag S, Matthiesen S, Juergens UR, Racke K. Muscarinic receptors mediate stimulation of collagen synthesis in human lung fibroblasts. Eur Respir J 2008; 32: 555-562.
45. Matthiesen S, Bahulayan A, Holz O, Racke K. MAPK pathway mediates muscarinic receptor-induced human lung fibroblast proliferation. Life Sci 2007; 80: 2259-2262.
46. Degirolamo C, Modica S, Palasciano G, Moschetta A. Bile acids and colon cancer: Solving the puzzle with nuclear receptors. Trends Mol Med 2011; 17: 564-572.
47. Tully BT, Li MS, Sun Y, Berkowitz J, Chai TC. Defects in muscarinic receptor cell signaling in bladder urothelial cancer cell lines. Urology 2009; 74: 467-473.
48. Song P, Sekhon HS, Lu A, et al. M3 muscarinic receptor antagonists inhibit small cell lung carcinoma growth and mitogen-activated protein kinase phosphorylation induced by acetylcholine secretion. Cancer Res 2007; 67: 3936-3944.
49. Song P, Sekhon HS, Fu XW, et al. Activated cholinergic signaling provides a target in squamous cell lung carcinoma. Cancer Res 2008; 68: 4693-6700.
50. Gutkind JS, Novotny EA, Brann MR, Robbins KC. Muscarinic acetylcholine receptor subtypes as agonist-dependent oncogenes. Proc Natl Acad Sci U S A 1991; 88: 4703-4707.
51. Yang WL, Frucht H. Cholinergic receptor up-regulates COX-2 expression and prostaglandin E(2) production in colon cancer cells. Carcinogenesis 2000; 21: 1789-1793.
52. Belo A, Cheng K, Chahdi A, et al. Muscarinic receptor agonists stimulate human colon cancer cell migration and invasion. Am J Physiol Gastrointest Liver Physiol 2011; 300: G749-760.
53. Cesario A, Russo P, Nastrucci C, Granone P. Is α7-nAChR a possible target for lung cancer and malignant pleural mesothelioma treatment? Curr Drug Targets 2012; 13: 688-694.
54. Trombino S, Bisio A, Catassi, A, et al. Role of the nonneuronal human cholinergic system in lung cancer and mesothelioma: possibility of new therapeutic strategies. Curr Med Chem Anticancer Agents 2004; 4: 535-542.
55. Wu CH, Lee CH, Ho YS. Nicotinic acetylcholine receptorbased blockade: applications of molecular targets for cancer therapy. Clin Cancer Res 2011; 17: 3533-3541.
56. Al-Wadei HA, Al-Wadei MH, Schuller HM. Cooperative regulation of non-small cell lung carcinoma by nicotinic and beta-adrenergic receptors: a novel target for intervention. PLoS One 2012; 7: e29915.
57. Grando SA. Basic and clinical aspects of non-neuronal acetylcholine: biological and clinical significance of noncanonical ligands of epithelial nicotinic acetylcholine receptors. J Pharmacol Sci 2008; 106: 174-179.
58. Monod J, Wyman J, Changeux JP. On the nature of allosteric transitions: a plausible model. J Mol Biol 1965; 12: 88-118.
59. Changeux JP. Allosteric receptors: from electric organ to cognition. Annu Rev Pharmacol Toxicol 2010; 50: 1-38.
60. Maksay G. Ligand-gated pentameric ion channels, from binding to gating. Curr Mol Pharmacol 2009; 2: 253-262.
61. Villarroya M, Garcia AG, Marco-Contelles J, Lopez MG. An update on the pharmacology of galantamine. Expert Opin Investig Drugs 2007; 16: 1987-1998.
62. Trombino S, Cesario A, Margaritora S, et al. Alpha7-nicotinic acetylcholine receptors affect growth regulation of human mesothelioma cells: role of mitogen-activated protein kinase pathway. Cancer Res 2004; 64: 135-145.
63. Krais AM, Hautefeuille AH, Cros MP, et al. CHRNA5 as negative regulator of nicotine signaling in normal and cancer bronchial cells: effects on motility, migration and p63 expression. Carcinogenesis 2011; 32: 1388-1395.
64. Cucina A, Dinicola S, Coluccia P, et al. Nicotine stimulates proliferation and inhibits apoptosis in colon cancer cell lines through activation of survival pathways. J Surg Res 2012; 178: 233-241.
65. Al-Wadei MH, Al-Wadei HA, Schuller HM. Pancreatic cancer cells and normal pancreatic duct epithelial cells express an autocrine catecholamine loop that is activated by nicotinic acetylcholine receptors α3, α5, and α7. Mol Cancer Res 2012; 10: 239-249.
66. Catassi A, Paleari L, Servent D, et al. Targeting alpha7-nicotinic receptor for the treatment of pleural mesothelioma. Eur J Cancer 2008; 44: 2296-2311.
67. Grozio A, Paleari L, Catassi A, et al. Natural agents targeting the alpha7-nicotinic-receptor in NSCLC: a promising prospective in anti-cancer drug development. Int J Cancer 2008; 122: 1911-1915.
68. Narumoto O, Horiguchi K, Horiguchi S, et al. Downregulation of secreted lymphocyte antigen-6/urokinase-type plasminogen activator receptor-related peptide-1 (SLURP-1), an endogenous allosteric alpha7 nicotinic acetylcholine receptor modulator, in murine and human asthmatic conditions. Biochem Biophys Res Commun 2010; 398: 713-718.
69. Kalantari-Dehaghi M, Bernard HU, Grando SA. Reciprocal effects of NNK and SLURP-1 on oncogene expression in target epithelial cells. Life Sci 2012; 91: 1122-1125.
70. Fu XW, Rekow SS, Spindel ER. The ly-6 protein, lynx1, is an endogenous inhibitor of nicotinic signaling in airway epithelium. Am J Physiol Lung Cell Mol Physiol 2012; 303: L661-668.
71. Lien YC, Wang W, Kuo LJ, et al. Nicotine promotes cell migration through alpha7 nicotinic acetylcholine receptor in gastric cancer cells. Ann Surg Oncol 2011; 18: 2671-2679.
72. Lee CH, Chang YC, Chen CS, et al. Crosstalk between nicotine and estrogen-induced estrogen receptor activation induces α9-nicotinic acetylcholine receptor expression in human breast cancer cells. Breast Cancer Res Treat 2011; 129: 331-345.
73. Chen CS, Lee CH, Hsieh CD, et al. Nicotine-induced human breast cancer cell proliferation attenuated by garcinol through down-regulation of the nicotinic receptor and cyclin D3 proteins. Breast Cancer Res Treat 2011; 125: 73-87.
74. Shih YL, Liu HC, Chen CS, et al. Combination treatment with luteolin and quercetin enhances antiproliferative effects in nicotine-treated MDA-MB-231 cells by down-regulating nicotinic acetylcholine receptors. J Agric Food Chem 2010; 58: 235-241.
75. Daniell HW. Estrogen receptors, breast cancer, and smoking. N Engl J Med 1980; 302: 1478.
76. Al-Delaimy WK, Cho E, Chen WY, Colditz G, Willet WC. A prospective study of smoking and risk of breast cancer in young adult women. Cancer Epidemiol Biomarkers Prev 2004; 13: 398-404.
77. Pritchard KI. Endocrine therapy: is the first generation of targeted drugs the last? Intern Med 2013; 274: 144-152.
78. Tu SH, Ku CY, Ho CT, et al. Tea polyphenol (-)-epigallocatechin-3-gallate inhibits nicotine-and estrogeninduced α9-nicotinic acetylcholine receptor upregulation in human breast cancer cells. Mol Nutr Food Res 2011; 55: 455-466.
79. Russo P, Del Bufalo A, Cesario A. Flavonoids acting on DNA topoisomerases: recent advances and future perspectives in cancer therapy. Curr Med Chem 2012; 19: 5287-5293.
80. Ami N, Koga K, Fushiki H, et al. Selective m(3) muscarinic receptor antagonist inhibits small-cell lung carcinoma growth in a mouse orthotopic xenograft model. J Pharmacol Sci 2011; 116: 81-8.
81. Rodrigo GJ, Nannini LJ. Tiotropium for the treatment of stable chronic obstructive pulmonary diseases: a systemic review with meta-analysis. Pulm Pharmacol Ther 2007; 20: 495-502.
82. Asano K, Shikam Y, Shibuya Y, et al. Suppressive activity of tiotropium bromide on matrix metalloproteinase production from lung fibroblasts in vitro. Int J Chron Obstruct Pulmon Dis 2008; 3: 781-789.
83. Asano K, Shikam Y, Shoji N, et al. Tiotropium bromide inhibits TGF-β-induced MMP production from lung fibroblasts by interfering with Smad and MAPK pathways in vitro. Int J Chron Obstruct Pulmon Dis 2010; 5: 277-286.
84. Song P, Olivas AS, Spindel ER. Tiotropium inhibits growth of squamous cell lung carcinoma (SCC) cell lines in vitro and also inhibits SCC growth in vivo in nude mice by inhalation. Available at: www.ersnet.org/learning...player/.../453.pdf. (Accessed January 18, 2013).
85. Rosemond E, Rossi M, McMillin SM, et al. Regulation of M3 muscarinic receptor expression and function by transmembrane protein 147. Mol Pharmacol 2011; 79: 251-261.
86. Bierut LJ. Convergence of genetic findings for nicotine dependence and smoking related diseases with chromosome 15q24-25. Trends Pharmacol Sci 2010; 31: 46-51.
87. Hung RJ, McKay JD, Gaborieau V, et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 2008; 452: 633-637.
88. Macqueen DA, Heckman BW, Blank MD, et al. Variation in the α 5 nicotinic acetylcholine receptor subunit gene predicts cigarette smoking intensity as a function of nicotine content. Pharmacogenomics J 2014; 14: 70-76.
89. Gu M, Dong X, Zhang X, et al. Strong association between two polymorphisms on 15q25.1 and lung cancer risk: a metaanalysis. PLoS One 2012; 7: e37970.
90. Chikova A, Bernard HU, Shchepotin IB, Grando SA. New associations of the genetic polymorphisms in nicotinic receptor genes with the risk of lung cancer. Life Sci 2012; 91: 1103-1108.
91. Chikova A, Grando SA. Naturally occurring variants of human Α9 nicotinic receptor differentially affect bronchial cell proliferation and transformation. PLoS One 2011; 6: e27978.
92. Pharmacogenomics: Knowledge and Implementation. rs16969968 at chr15:78882925 in CHRNA3, CHRNA5. Available at: http://www.pharmgkb.org/rsid/rs16969968. (Accessed April 27, 2012).
93. Ruggieri MR, Colton MD, Wang P, et al. Human prostate muscarinic receptor subtypes. J Pharmacol Exp Ther 1995; 274: 976-982.
94. Magnon C, Hall SJ, Lin J, et al. Autonomic nerve development contributes to prostate cancer progression. Science 2013; 341: 1236361.
95. Arredondo J, Arredondo J, Karlsson E, Wessler I, Grando SA. The Ras/Raf-1/MEK1/ERK signaling pathway coupled to integrin expression mediates cholinergic regulation of keratinocyte directional migration. J Biol Chem 2005; 280: 39220-39228.
96. Marshall E. Cancer research and the $90 billion metaphor. Science 2011; 331: 1540-1541.
97. Brenner H. Long-term survival rates of cancer patients achieved by the end of the 20th century: A period analysis. Lancet 2002; 360: 1131-1135.
98. Breitkreutz D, Hlatky L, Rietman E, Tuszynski JA. Molecular signaling network complexity is correlated with cancer patient survivability. Proc Natl Acad Sci U S A 2012; 109: 9209-9212.
99. Weinstein IB, Joe A. Oncogene addiction. Cancer Res 2008; 68: 3077-3080.
100. [100] Tong D, Jiang J. Complex behaviours-new targets against cancer. Nat Rev Clin Oncol 2013; 10: 79.
101. [101] Cesario A, Marcus F. Cancer systems biology, bioinformatics and medicine. Research and clinical applications. Springer Sciences 2011.
102. [102] Saetzler K, Sonnenschein C, Soto AM. Systems biology beyond networks: generating order from disorder through self-organization. Semin Cancer Biol 2011; 21: 165-174.
103. [103] Jeong H, Tombor B, Albert R, Oltvai ZN, Barabasi AL. The large-scale organization of metabolic networks. Nature 2000; 407: 651-654.
104. [104] Albert R, Jeong H, Barabasi AL. Error and attack tolerance of complex networks. Nature 2000; 406: 378-382.
105. [105] West J, Bianconi G, Severini S, Teschendorff AE. Differential network entropy reveals cancer system hallmarks. Sci Rep 2012; 2: 802.
106. [106] Faratian D, Clyde RG, Crawford JW, Harrison DJ. Systems pathology-taking molecular pathology into a new dimension. Nat Rev Clin Oncol 2009; 6: 455-464.
107. [107] Remacle F, Kravchenko-Balasha N, Levitzki A, Levine RD. Information-theoretic analysis of phenotype changes in early stages of carcinogenesis. Proc Natl Acad Sci U S A 2010; 107: 10324-10329.
108. [108] Kravchenko-Balasha N, Remacle F, Gross A, et al. Convergence of logic of cellular regulation in different premalignant cells by an information theoretic approach. BMC Syst Biol 2011; 5: 42.
109. [109] Kravchenko-Balasha N, Levitzki A, Goldstein A, et al. On a fundamental structure of gene networks in living cells. Proc Natl Acad Sci U S A 2012; 109: 4702-4707.
110. [110] Gatenby RA, Silva AS, Gillies RJ, Frieden BR. Adaptive therapy. Cancer Res 2009; 69: 4894-4903.
111. Arredondo J, Chernyavsky AI, Jolkovsky DL, Pinkerton KE, Grando SA. Receptor-mediated tobacco toxicity: cooperation of the Ras/Raf-1/MEK1/ERK and JAK-2/STAT-3 pathways downstream of alpha7 nicotinic receptor in oral keratinocytes. FASEB J 2006; 20: 2093-2101.
112. [112] Chu M, Guo J, Chen CY. Long-term exposure to nicotine, via ras pathway, induces cyclin D1 to stimulate G1 cell cycle transition. J Biol Chem 2005; 280: 6369-6379.
113. [113] Cohen N, Kravchenko-Balasha N, Klein S, Levitzki A. Heterogeneity of gene expression in murine squamous cell carcinoma development-the same tumor by different means. PLoS One 2013; 8: e57748.